title: The Treatment of Hepatorenal Syndrome.
abstract: Hepatorenal syndrome (HRS) is a severe complication that often occurs in patients with cirrhosis and ascites. HRS is a functional renal failure that develops mainly as a consequence of a severe cardiovascular dysfunction which is characterized by an extreme splanchnic arterial vasodilation and a reduction of cardiac output. HRS may develop in two clinical types: as an acute and rapidly progressive renal failure (AKI-HRS) or as chronic and not progressive renal failure (CKD-HRS). Several small studies and some randomized control studies have been published on the use of terlipressin plus albumin in the treatment of HRS, mainly on AKI-HRS. Terlipressin plus albumin was shown to improve renal function in almost 35-45% of patients with AKI-HRS, as well as to improve short-term survival in these patients. Terlipressin was most commonly used by intravenous boluses moving from an initial dose of 0.5-1 mg every 4 h to 3 mg every 4 h in the case of a nonresponse. In other studies, terlipressin was also given by continuous intravenous infusion. Thus, the best way to administer terlipressin in the treatment of HRS has not yet been defined. α-Adrenergic drugs, such as intravenous norepinephrine or oral midodrine plus subcutaneous octreotide, administered with albumin have also been used in the treatment of AKI-HRS, with promising results. However, we need further studies in order to define whether they can represent a real therapeutic alternative. In conclusion, available data are sufficient to state that the use of terlipressin plus albumin has really changed the management of HRS. Nevertheless, some crucial unsolved issues still exist, in particular: (a) how to predict nonresponse to treatment, (b) how to manage nonresponse to treatment and (c) how to consider the response in those patients who are candidates for liver transplant in the priority allocation process.
authors.affiliation: U.O. Clinica Medica V, University of Padua, Padua, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Cavallin
authors.forename: Silvano
authors.initials: S
authors.lastname: Fasolato
authors.forename: Simona
authors.initials: S
authors.lastname: Marenco
authors.forename: Salvatore
authors.initials: S
authors.lastname: Piano
authors.forename: Marta
authors.initials: M
authors.lastname: Tonon
authors.forename: Paolo
authors.initials: P
authors.lastname: Angeli
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000418:Albumins / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077585:Terlipressin
chemical_list: D000317:Adrenergic alpha-Antagonists; D000418:Albumins; D000959:Antihypertensive Agents; D008236:Lypressin; D000077585:Terlipressin